M3V MeVis Medical Solutions AG
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; as well as provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. In addition, the company provides three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians; and internet-based special applications in teleradiology. The company was founded in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Corporation.…
Industry Peers
Health Information ServicesKey Statistics
About MeVis Medical Solutions (ETR: M3V)
›
MeVis Medical Solutions (ETR: M3V) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 127 employees.
The shares were at 22.00 EUR on 20 November 2026, down 8.0% over 52 weeks. Its 52-week range is 19.10 EUR to 26.80 EUR: the price is 17.9% below the high and 15.2% above the low.
At a market capitalisation of 40.04M EUR, it trades at 51.2 times trailing earnings. The median trailing P/E of its 15 largest Health Information Services peers is 39.9, a premium of 28% for M3V. It pays a dividend yielding 4.52% (it pays out 227% of its earnings), against a median of 0.53% among the dividend payers in that peer group.
MeVis Medical Solutions reports return on equity of 17.8%, an operating margin of 4.2% and revenue down 6.8% year over year.
It holds more cash than debt, a net cash position of 3.65M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.